Symbiotix Biotherapies declares agreement with Paragon Bioservices for Process Development & Manufacturing

Leading venture backed microbiome company growing novel molecular therapeutics based on the human microbiome, asserted that it intends to enter into an agreement with Paragon Bioservices, Inc for process development and manufacturing.

Paragon Bioservices, Inc, proves itself to be a global leader in the field of manufacturing complex biopharmaceuticals acclaimed for transforming research to finished drug products for clinical usage.

As per the the features of the agreement, Paragon wishes to continue its work on Symbiotix’s lead program to finish enhancement of the downstream process for SYMB- 104 assuring production of clinical material at large. Symbiotix’s proprietary engineered production strain of B. Fragilis, a strain engineered to serve as an alternative to immunomodulatory polysaccharide thus serving the purpose without touching upon other capsular polysaccharides . SYMB-104 is a Reglemer based on a specific capsular polysaccharide produced by B. fragilis that is capable of modulating regulatory T cell activity, and is protected by issued composition-of-matter patents. However, conditions of the manufacturing agreement were not divulged.

Peter Buzy, Chief Executive Officer of Paragon stated excitement over the deal “We are pleased that Symbiotix Biotherapies has chosen Paragon Bioservices as their process development and manufacturing partner and believe that it is testament to the value that our scientific expertise brings to a program.”